RxDoctor Payments Data

Ladan Bakhtari, MD

Internal Medicine · Plano, TXNPI 1275602799

Payments from drug & device makers

$51,720in general payments, 2019–2025

Across 326 payments — averaging $158.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$45K
  • Novo Nordisk$790
  • AbbVie$664
  • Echosens North America, Inc.$541
  • Johnson & Johnson$481
  • Boehringer Ingelheim International GmbH$431
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$6,22598%
  • Education$871%
  • Entertainment$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,720 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$188,293
Medicare patients
222
Services billed
4,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf89$27,798
TradjentaLinagliptin17$20,503
JanumetSitagliptin Phos/Metformin Hcl17$20,470
OzempicSemaglutide12$16,017
EliquisApixaban12$14,489
FarxigaDapagliflozin Propanediol13$14,447
JardianceEmpagliflozin11$11,327
ShingrixVaricella-Zoster Ge/As01b/Pf33$7,316
SynthroidLevothyroxine Sodium26$2,835
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf35$2,453
Rosuvastatin Calcium163$2,429
Metoprolol Succinate57$687
Levothyroxine Sodium73$529
Omeprazole26$494
Pioglitazone Hcl30$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix$251$35,114122 claims
Boehringer IngelheimTradjenta, Jardiance$277$31,83128 claims
MerckJanumet$120$20,47017 claims
Novo NordiskOzempic$790$16,01712 claims
PfizerEliquis$117$14,48912 claims
AstraZenecaFarxiga$45,308$14,44713 claims
AbbVieSynthroid$664$2,83526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →